Leerink Partnrs Has Negative Estimate for Humana Q4 Earnings

Humana Inc. (NYSE:HUM) – Equities research analysts at Leerink Partnrs reduced their Q4 2025 earnings per share estimates for Humana in a report issued on Wednesday, November 5th. Leerink Partnrs analyst W. Mayo now forecasts that the insurance provider will earn ($3.88) per share for the quarter, down from their prior estimate of ($3.40). The consensus estimate for Humana’s current full-year earnings is $16.47 per share. Leerink Partnrs also issued estimates for Humana’s Q3 2026 earnings at $1.36 EPS, Q4 2026 earnings at ($5.03) EPS, FY2026 earnings at $13.72 EPS, FY2027 earnings at $21.79 EPS and FY2029 earnings at $45.95 EPS.

A number of other analysts have also recently commented on the stock. Evercore ISI assumed coverage on shares of Humana in a research report on Monday, September 22nd. They issued an “in-line” rating and a $295.00 price objective for the company. Wall Street Zen downgraded Humana from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Wolfe Research raised their price target on Humana from $283.00 to $313.00 and gave the stock an “outperform” rating in a research report on Monday, October 6th. Mizuho boosted their price objective on Humana from $300.00 to $345.00 and gave the company an “outperform” rating in a research report on Thursday, October 9th. Finally, Bank of America increased their target price on Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a research note on Friday, October 10th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $299.22.

Humana Stock Up 0.1%

Shares of NYSE HUM opened at $251.46 on Monday. Humana has a 52-week low of $206.87 and a 52-week high of $315.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The stock has a market cap of $30.24 billion, a P/E ratio of 19.30, a P/E/G ratio of 1.71 and a beta of 0.42. The firm has a 50 day moving average price of $278.04 and a 200 day moving average price of $258.86.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.29. The company had revenue of $32.65 billion during the quarter, compared to analyst estimates of $31.99 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company earned $4.16 EPS.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, December 26th. Humana’s dividend payout ratio is currently 33.18%.

Institutional Trading of Humana

Several institutional investors and hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Humana by 16.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock valued at $300,728,000 after acquiring an additional 158,528 shares during the last quarter. Focus Partners Wealth grew its holdings in shares of Humana by 104.2% during the 1st quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock valued at $1,701,000 after purchasing an additional 3,281 shares during the last quarter. Envestnet Asset Management Inc. increased its position in Humana by 2.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider’s stock worth $33,256,000 after purchasing an additional 2,950 shares in the last quarter. Circle Wealth Management LLC bought a new position in Humana in the 1st quarter valued at approximately $425,000. Finally, Kera Capital Partners Inc. acquired a new stake in Humana in the second quarter valued at approximately $253,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.